<DOC>
	<DOC>NCT00700193</DOC>
	<brief_summary>The purpose of this study is to determine the Safety, Tolerability &amp; Immunogenicity of CSL Limited's Influenza Virus Vaccine in a two dose primary vaccination series, with a 12-month booster vaccination, in a paediatric population equal to or greater than 6 months to less than 9 years old.</brief_summary>
	<brief_title>A Study of the Safety, Tolerability &amp; Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Be healthy male or female children, aged = or &gt; 6 months to &lt; 9 years at the time of first study vaccination; Note: = or &gt; 6 refers to 6 calendar months 2. Parent(s) or Guardian(s) to provide written informed consent to participate in the study; 3. Be able to provide a prevaccination sample of up to 5mL of venous blood without undue distress/discomfort and 4. Be born after a normal gestation period (between 36 and 42 weeks). 1. Known allergy to eggs, chicken feathers, neomycin, polymyxin, or any components of the vaccine; 2. Previous influenza vaccination; 3. Clinical signs of active infection and/or an axillary temperature of = or &gt;37.5 degrees Celsius or oral temperature of = or &gt;38 degrees Celsius at study entry. Study entry may be deferred for such individuals, at the discretion of the Principal Investigator; 4. Confirmed or suspected immunosuppressive condition (including cancer), or a previously diagnosed (congenital or acquired) immunodeficiency disorder (including HIV); 5. Current (or within the 90 days prior to receiving the Study Vaccine) treatment with immunosuppressive or immunomodulative medication, including systemic corticosteroids, as follows: •Chronic or long term corticosteroids: &gt;0.5mg/kg/day of oral prednisolone or equivalent (Note: Use of topical or inhalant corticosteroids prior to administration of the Study Vaccine or throughout the Study is acceptable). 6. Administration of immunoglobulins and/or any blood products since birth or planned administration of such blood products during the study period; 7. Participation in a clinical study or use of an investigational compound (ie a new chemical or biological entity not registered for clinical use), within the 90 days prior to receiving the Study Vaccine or be planning to enter such a study during the study period; 8. Current treatment with cytotoxic drugs or treatment within the 6 months prior to administration of the Study Vaccine; 9. Have a known history of GuillainBarré Syndrome; 10. Have a major congenital defect or serious illness and 11. Have a history of neurologic disorders or seizures</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>